Biomed Group
Long/short equity, healthcare, biotech

Aratana Therapeutics: A Growing Player Within The Emerging Pet Therapeutics Market

Over the last several decades, the animal health market has outgrown the U.S. economy and been more resistant to economic cycles. Moreover, the vet market is an attractive vehicle for investors to participate in the growth of the broader healthcare industry without reimbursement risk. U.S. consumers will spend an estimated $55.53 billion on pets this year - a number that has been growing at a pace of more than 5% over the past decade. Therapeutics constitutes a small portion of this market but is poised to expand as pet care becomes more complex and companies roll out new products for unmet needs. In this article, we decided to evaluate Aratana Therapeutics (PETX), a small-cap biopharmaceutical company developing...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details